The devotion to surrogate outcomes in drug development for liver disease

The devotion to surrogate outcomes in drug development for liver disease, Published online: 29 November 2017; doi:10.1038/nrgastro.2017.155

Surrogate end points are often used in clinical trials where the time to clinical outcomes is long. In patients with liver disease, these surrogate outcomes are rarely validated. Without validation, treatment effects reported in trials might not directly translate to patient benefit after licensing.

中文翻译：

---

致力于替代肝病药物开发的成果

致力于替代肝病药物开发的成果

致力于替代肝病药物研发成果的意愿，在线发布：2017年11月29日；doi：10.1038 / nrgastro.2017.155

替代终点通常用于达到临床结果时间较长的临床试验中。在患有肝病的患者中，这些替代结果很少得到证实。没有验证，试验中报告的治疗效果可能不会在许可后直接转化为患者利益。